As employers navigate the challenges of providing comprehensive health care solutions, cost-effective standalone telehealth options continue to emerge as a beacon of hope.

Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson presented their arguments on Thursday in New Jersey district court, just a week after a similar AstraZeneca suit was dismissed by a federal judge in Delaware.

While the $20-a-month cost for Opill will likely be covered by health insurance with a prescription from a doctor, it may also be available for reimbursement under FSA or HSA accounts, depending on individual employer restrictions.

For now, insurers and employers are still not required to cover certain free preventive care services, such as cancer screenings and HIV-preventing medications, until the federal appeals court makes its decision later this year.